08:00 Wed 19 Sep 2018
SkinBioTherapeutics - Human study commenced
Human study commenced
There are three elements to the human study: the first, already underway, is to assess skin irritancy; the second, due to commence on
Study one is a skin irritancy test using different concentrations of SkinBiotix® in the cream formulation. Five different concentrations of the technology will be compared with the base formulation (i.e. containing no SkinBiotix®) and an existing marketed dermatological cream. Thirty volunteers will be assessed for irritancy at various time points up to 72 hours. The results are expected in
Study two is an evaluation of the moisturisation potential of the SkinBiotix® cream formulation compared to the base formulation. The study will assess 20 participants, with approximately a 12 hour treatment period for each volunteer. The results are expected in
Study three is a test to determine whether the positive impact of the technology on the skin's barrier function, which has been demonstrated in laboratory studies, is replicated in human volunteers. The Company has now received final ethics approval for the commencement of this study. The study will be conducted with 120 female volunteers with self-assessed 'dry skin'. The first 20 volunteers will be treated in
Dr
"I am delighted that we now have all three aspects of our human study scheduled. Data from the two initial tests is expected in
-ENDS-
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by
For more information, please contact:
Dr.
|
Tel: +44 (0) 161 468 2760 |
|
Tel: +44 (0) 20 7213 0880 |
Turner Pope Investments (Joint Broker)
|
Tel: +44 (0) 20 3621 4120
Tel: +44 (0) 20 3861 6625 |
|
Tel: +44 (0) 20 7457 2020 |
About
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr.
SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer office of the
The Company joined AIM in
The Company is based in
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE